Life (May 2023)

Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy

  • Anastasia Papaporfyriou,
  • Konstantinos Bartziokas,
  • Daniela Gompelmann,
  • Marco Idzko,
  • Evangelia Fouka,
  • Stavrina Zaneli,
  • Petros Bakakos,
  • Stelios Loukides,
  • Andriana I. Papaioannou

DOI
https://doi.org/10.3390/life13061299
Journal volume & issue
Vol. 13, no. 6
p. 1299

Abstract

Read online

Chronic obstructive pulmonary disease (COPD) is considered one of the leading causes of mortality. Cardiovascular comorbidities are diagnosed often in COPD patients, not only because of the common risk factors these two diseases share, but also because of the systemic inflammation which characterizes COPD and has deleterious effects in the cardiovascular system. The comorbid cardiovascular diseases in COPD result in several difficulties in the holistic treatment of these patients and affect outcomes such as morbidity and mortality. Several studies have reported that mortality from cardiovascular causes is common among COPD patients, while the risk for acute cardiovascular events increases during COPD exacerbations and remains high for a long time even after recovery. In this review, we focus on the prevalence of cardiovascular comorbidities in COPD patients, presenting the evidence regarding the interaction of the pathophysiological pathways which characterize each disease. Furthermore, we summarize information regarding the effects of cardiovascular treatment on COPD outcomes and vice versa. Finally, we present the current evidence regarding the impact of cardiovascular comorbidities on exacerbations, quality of life and survival of COPD patients.

Keywords